Tariquidar
Tariquidar is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target ATP-dependent translocase ABCB1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 1 | 2 | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 2 |
| Adrenocortical carcinoma | D018268 | — | — | 1 | 1 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | 2 | 1 | — | — | — | 2 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | — | — | — | 1 |
| Adrenal cortex neoplasms | D000306 | — | C74.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Wilms tumor | D009396 | EFO_0000212 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tariquidar |
| INN | tariquidar |
| Description | Tariquidar is a member of benzamides. |
| Classification | Small molecule |
| Drug class | multidrug resistance inhibitors: quinoline derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2 |
Identifiers
| PDB | — |
| CAS-ID | 206873-63-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL348475 |
| ChEBI ID | — |
| PubChem CID | 148201 |
| DrugBank | DB06240 |
| UNII ID | J58862DTVD (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ABCB1
ABCB1
Organism
Homo sapiens
Gene name
ABCB1
Gene synonyms
MDR1, PGY1
NCBI Gene ID
Protein name
ATP-dependent translocase ABCB1
Protein synonyms
ATP-binding cassette sub-family B member 1, ATP-binding cassette, sub-family B (MDR/TAP), member 1, CD243, colchicin sensitivity, doxorubicin resistance, Multidrug resistance protein 1, P-glycoprotein 1, Phospholipid transporter ABCB1
Uniprot ID
Mouse ortholog
Abcb1b (18669)
ATP-dependent translocase ABCB1 (P06795)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,585 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use